Fresenius Medical Care North America Introduces Frenova Renal Research

  Fresenius Medical Care North America Introduces Frenova Renal Research

 Renal Research Organization is First of its Kind for Clinical Trial Services

Business Wire

WALTHAM, Mass. -- March 26, 2014

Fresenius Medical Care North America (FMCNA), the world’s largest provider of
dialysis services, today introduced its newly branded Frenova Renal Research
business, the only Phase I-IV drug and device clinical development partner
dedicated exclusively to renal research.

Since 2001, Frenova, formerly known as the Clinical Studies Group at FMCNA,
has supported sponsors and nephrologists conducting research specific to
kidney disease and its comorbid conditions.

“Frenova is a new name, but the company is built on more than a decade of
experience focused exclusively on the clinical development of new renal
therapies largely developed using the world’s largest dialysis treatment and
research network,” said Kurt Mussina, vice president and general manager of
Frenova. Frenova provides access to a network comprising more than 390,000
pre-dialysis patients with chronic kidney disease (CKD) and 183,000 active
dialysis patients with end stage renal disease (ESRD), as well as extensive
resources of real-world clinical data collected over the past two decades.

These resources, combined with Frenova’s bioinformatics and analytics
capabilities, provide an unparalleled asset for biopharmaceutical and medical
device companies seeking to assess protocol feasibility, optimize research
site selection and/or conduct highly targeted patient recruitment activities.

“The sheer depth of our renal expertise and our access to patients, sites,
investigators and data resources for both cross-sectional and longitudinal
analyses are indispensable assets for renal clinical development programs,”
said Mussina. “Developing treatments to improve the quality of life for people
with kidney disease has always been our singular objective. Our new identity
as Frenova reflects that mission and will play a key role in furthering it,”
Mussina added.

For more information, visit FrenovaRenalResearch.com or call 844.CKD.ESRD.
Frenova will also be exhibiting at the 23rd Annual Partnerships in Clinical
Trials — visit booth #402 or email Brigid.Flanagan@FrenovaRenalResearch.com to
schedule a meeting.

About Frenova Renal Research

Frenova Renal Research, a Fresenius Medical Care North America (FMCNA)
company, is the only Phase I-IV drug and device clinical development services
provider dedicated exclusively to renal research. Backed by the world’s
largest provider of dialysis services and a network of more than 390,000
active chronic kidney disease (CKD) patients and 183,000 active end stage
renal disease (ESRD) patients, Frenova is an unparalleled resource for
biotech, pharmaceutical and medical device companies worldwide. With
comprehensive clinical development and bioinformatics and analytics services
and an extensive renal site network, Frenova is your foremost renal research
partner. Visit www.FrenovaRenalResearch.com for more information.

About Fresenius Medical Care North America

Through our leading network of more than 2,150 dialysis facilities in North
America and our vascular access centers, laboratory, pharmacy and affiliated
hospitals and nephrology practices, Fresenius Medical Care provides renal
services to hundreds of thousands of people throughout the United States,
Mexico and Canada. We are also the continent’s top producer of dialysis
equipment, dialyzers and related disposable products and a major supplier of
renal pharmaceuticals. For more information about the company,
visitwww.fmcna.com; for information about patient services, visit
www.ultracare-dialysis.com.

Contact:

Fresenius Medical Care North America
Lea Studer, 308-237-5567
lea@scorrmarketing.com
 
Press spacebar to pause and continue. Press esc to stop.